Antiepileptic drugs: From scientific evidence to clinical practice

Neurologist

Volumn 13, Issue 6 SUPPL. 1, 2007, Pages

  García Morales, Irene ^a   Rieger, Jerónimo Sancho ^b   Gil Nagel, Antonio ^c   Fernández, José Luís Herranz ^d  

^a SCHOOL OF MEDICINE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL RUBER INTERNACIONAL   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Adverse effects; Epilepsy treatment; Monotherapy; Pharmacoeconomics

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EPILEPSY; EVIDENCE BASED MEDICINE; GENERALIZED EPILEPSY; HUMAN; IDIOPATHIC DISEASE; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT CONTRAINDICATION;

ANTICONVULSANTS; BIOMEDICAL RESEARCH; EPILEPSY; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 37349094313     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31815bb3b7     Document Type: Review

References (60)

1. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72.
2. Cook DJ, Greengold NL, Ellrodt AG, et al. The relation between systematic reviews and practice guidelines. Ann Intern Med. 1997;127:210-216.
3. Franklin GM, Zahn CA. AAN clinical practice guidelines: above the fray. Neurology. 2002;59:975-976.
4. Gilliam FG. Epilepsy - success in clinical practice: translating trials to practice. Eur J Neurol. 2005;12(Suppl 4):22-29.
5. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs. I. Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004;45:401-409.
6. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs. II. Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004;45:410-423.
7. Hixson JD, French JA. Guidelines for new antiepileptic drug evaluation. Rev Neurol Dis. 2004;1(Suppl 1):S18-S26.
8. SIGN. Diagnosis and Management of Epilepsy in Adults. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network; 2003.
9. Perucca E. NICE guidance on newer drugs for epilepsy in adults. BMJ. 2004;328:1273-1274.
10. NICE. Epilepsy. The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care. NICE Guidelines. London, UK: Department of Health; 2004.
11. PRODIGY Guidance. Epilepsy. PRODIGY Knowledge Guidance. Available at: http://www.Prodigy.nhs.uk/guidance.asp?gt-epilepsy. 2006.
12. Rufo M, Peña P, Elices E y Cruz-Campos G. Guía oficial para el diagnóstico y tratamiento de la epilepsia 2004. Prous Ed Barcelona. 2004:1-353.
13. Neurologia SCd. El Tratamiento de las Epilepsias. Guía Terapéutica. Available at: http://www.todoepilepsia.com/documento/ Guia_SCN.pdf. 2003.
14. Sánchez JC, Galán JM, Camino R, et al. Guía Terapéutica en Epilepsia de la Sociedad Andaluza de Epilepsia 2005: II. Terapéutica Antiepiléptica Crónica en el Adulto y en el Niño. Rev Neurol. 2005;40:619-626.
15. Molins A. Guías de Tratamiento de las Epilepsias: Una Revisión Crítica. 2006.
16. Karceski S, Morrell M, Carpenter D. The expert consensus guideline series treatment of epilepsy. Epilepsy Behav. 2001;2:A1-A50.
17. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. 2005;7(Suppl 1):S1-64; quiz S65-S67.
18. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094-1120.
19. Willmore LJ. Antiepileptic drugs and neuroprotection: current status and future roles. Epilepsy Behav. 2005;7(Suppl 3):S25-S28.
20. Garga N, Lowenstein DH. Posttraumatic epilepsy: a major problem in desperate need of major advances. Epilepsy Curr. 2006;6:1-5.
21. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470-472.
22. Leone MA, Solari A, Beghi E. Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy. Neurology. 2006;67:2227-2229.
23. Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005;365:2007-2013.
24. Musicco M, Beghi E, Solari A, et al. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology. 1997;49:991-998.
25. Chadwick D. Starting and stopping treatment for seizures and epilepsy. Epilepsia. 2006;47(Suppl 1):58-61.
26. Gilliam FG, Fessler AJ, Baker G, et al. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology. 2004;62:23-27.
27. King MA, Newton MR, Jackson GD, et al. Epileptology of the firstseizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients. Lancet. 1998;352:1007-1011.
28. Gil-Nagel A. Review of new antiepileptic drugs as initial therapy. Epilepsia. 2003;44(Suppl 4):3-10.
29. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319.
30. Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res. 2003;57:1-13.
31. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000;9:464-468.
32. Marson AG, Williamson PR, Clough H, et al. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia. 2002;43:505-513.
33. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1016-1026.
34. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology. 2000;55:1758.
35. Specchio LM, Gambardella A, Giallonardo AT, et al. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res. 2006;71:32-39.
36. Biton V, Bourgeois BF. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol. 2005;62:1705-1708.
37. Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord. 2004;6:267-270.
38. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000-1015.
39. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402-408.
40. Arroyo S, Brodie MJ, Avanzini G, et al. Is refractory epilepsy preventable? Epilepsia. 2002;43:437-444.
41. French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60:1631-1637.
42. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45:20-27.
43. Beydoun A, Uthman B, Ramsay R, et al. Pregabalin add-on trial: a double-blind, multicenter study in patients with partial epilepsy. Epilepsia. 1999;40:108.
44. Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, doseranging trial of retigabine for partial-onset seizures. Neurology. 2007;68:1197-1204.
45. French JA. Refractory epilepsy: clinical overview. Epilepsia. 2007;48(Suppl 1):3-7.
46. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314:180-181.
47. Berg AT, Langfitt J, Shinnar S, et al. How long does it take for partial epilepsy to become intractable? Neurology. 2003;60:186-190.
48. Shorvon S. The treatment of chronic epilepsy: a review of recent studies of clinical efficacy and side effects. Curr Opin Neurol. 2007;20:159-163.
49. Armijo J, Adin J. Bases farmacocinéticas para la asociación de antiepilépticos. Rev Neurol. 1997;25:382-395.
50. Armijo J, Cuadrado A. Bases farmacodinámicas para la asociación de antiepilépticos. Rev Neurol. 1997;25:363-373.
51. Perucca E, Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs. 2005;19:897-908.
52. Brodie MJ. Management strategies for refractory localization-related seizures. Epilepsia. 2001;42(Suppl 3):27-30.
53. Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a U. K. regional study. Epilepsia. 1998;39:776-786.
54. Kotsopoulos IA, Evers SM, Ament AJ, et al. The costs of epilepsy in three different populations of patients with epilepsy. Epilepsy Res. 2003;54:131-140.
55. van Hout B, Gagnon D, Souetre E, et al. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdom. Epilepsia. 1997;38:1221-1226.
56. Levy P. Economic evaluation of antiepileptic drug therapy: a methodologic review. Epilepsia. 2002;43:550-558.
57. Blais L, Sheehy O, St-Hilaire JM, et al. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. Pharmacoeconomics. 2005;23:493-503.
58. Knoester PD, Boendermaker AJ, Egberts AC, et al. Cost-effectiveness of add-on lamotrigine therapy in clinical practice. Epilepsy Res. 2005;67:143-151.
59. Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess. 2005;9:1-157, iii-iv.
60. Argumosa A, Herranz JL. Childhood epilepsy: a critical review of cost-of-illness studies. Epileptic Disord. 2004;6:31-40.